Why Dogwood Therapeutics, Inc.’s (DWTX) Stock Is Up 7.63%
As of Monday, August 24, Dogwood Therapeutics, Inc.’s DWTX share price has surged by 7.63%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
Commentary & Analysis
Why Dogwood Therapeutics, Inc.’s (DWTX) Stock Is Up 5.02%
As of Monday, August 24, Dogwood Therapeutics, Inc.’s DWTX share price has surged by 5.02%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Dogwood Therapeutics, Inc.’s (DWTX) Stock Is Up 7.03%
As of Monday, August 24, Dogwood Therapeutics, Inc.’s DWTX share price has surged by 7.03%, which has investors questioning if this is right time to sell.Michael Rose
Why Dogwood Therapeutics, Inc.’s (DWTX) Stock Is Up 6.22%
As of Friday, August 21, Dogwood Therapeutics, Inc.’s DWTX share price has surged by 6.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Dogwood Therapeutics, Inc.’s (DWTX) Stock Is Up 5.43%
As of Wednesday, August 12, Dogwood Therapeutics, Inc.’s DWTX share price has surged by 5.43%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | DWTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $87.0 | $285.0 | 20% |
|
| Shares Out (Mil) | 34.1 | 53.9 | 39% |
|
| Institutional Ownership | 99.6% | 93.2% | 91% |
|
| Float (Mil) | 5.8 | 41.4 | 13% |
|
| Beta | 1.76 | 0.95 | 88% |
|
| Avg Daily Volume (000s) | 70 | 523 | 31% |
|
| Price Change (52-week) |
(48.2%) | 58.8% | 15% |
|
| Growth | DWTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (27.2%) | (10.1%) | 15% |
|
| EPS (5yr) | 32.9% | 15.8% | 83 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.6%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | DWTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($36) | ($43) | 19% |
|
| EPS (TTM) | ($1.712) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($31) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $69 | $186 | 18% |
|
| Valuation | DWTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.26 | 2.85 | 31% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DWTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.5% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (40.7%) | (47.3%) | 14% |
|
| ROE | (143.4%) | (55.1%) | 6% |
|
| Liabilities to Assets | 15.1% | 29.6% | 9% |
|
| F-Score | 3 | 3 | 18% |
|
Dogwood Therapeutics, Inc. did not pass any screens on 8/24/2026.
